Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bryan Webb
TGF-β/Activin Signaling Promotes CDK7 Inhibitor Resistance in Triple Negative Breast Cancer Cells through Upregulation of Multidrug Transporters
Abstract Cyclin dependent kinase 7 (CDK7) is a master regulatory kinase that drives cell cycle progression and stimulates expression of oncogenes in a myriad of cancers. Inhibitors of CDK7 (CDK7i) are currently in clinical trials; however, as with many cancer therapies, patients will most likely experience recurrent disease due to acquired resistance. Identifying targets underlying CDK7i resistance will facilitate prospective development of new therapies that can circumvent such resistance.
The transcriptional repressor BCL11A promotes breast cancer metastasis
Author contributions—D. D. S., P. Y., G. B., and R. A. K. conceptualization; D. D. S., M. M. H., N. N. I., B. M. W., S. S., S. T. S., and D. D. L. data curation; D. D. S., N. N. I., K. L. W.-B., S. S., S. T. S., and D. D. L. formal analysis; D. D. S., M. M. H., N. N. I., S. S., and S. T. S. investigation; D. D. S., M. M. H., N. N. I., B. M. W., K. L. W.-B., S. S., and D. D. L. methodology; D. D. S., M. M. H., N. N. I., B. M. W., K. L. W.-B., P. Y., G. B., S. S., S. T. S., V. V., and D. D. L. writing-original draft; D. D. S., M. M. H., N. N. I., B. M. W., K. L. W.-B., P. Y., G.
The transcriptional repressor BCL11A promotes breast cancer metastasis
Author contributions: D.D.S., P.Y., G.B., and R.A.K. conceptualization; D.D.S., M.M.H., N.N.I., B.M.W., S.S., S.T.S., and D.D.L. data curation; D.D.S., N.N.I., K.L.W.-B., S.S., S.T.S., and D.D.L. formal analysis; D.D.S., M.M.H., N.N.I., S.S., and S.T.S. investigation; D.D.S., M.M.H., N.N.I., B.M.W., K.L.W.-B., S.S., and D.D.L. methodology; D.D.S., M.M.H., N.N.I., B.M.W., K.L.W.-B., P.Y., G.B., S.S., S.T.S., V.V., and D.D.L. writing-original draft; D.D.S., M.M.H., N.N.I., B.M.W., K.L.W.-B.,...
Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells
Sylvia S. Gayle‡1, Jennifer M. Sahni‡12, Bryan M. Webb‡, Kristen L. Weber-Bonk‡, Melyssa S. Shively‡, Raffaella Spina§, Eli E. Bar§, Mathew K. Summers¶ and Ruth A.
Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells
Sylvia S. Gayle1, Jennifer M. Sahni2, Bryan M. Webb1, Kristen L. Weber-Bonk3, Melyssa S. Shively3, Raffaella Spina4, Eli E. Bar3, Matthew K. Summers5 and Ruth A.
Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors
Therapeutics, Targets, and Chemical Biology Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors Jennifer M. Sahni, Sylvia S. Gayle, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Salendra Singh, Steven T. Sizemore, Nicole A. Restrepo, Gurkan Bebek, Peter C. Scacheri, Vinay Varadan, Matthew K. Summers and Ruth A. Keri
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bryan
Contact Bryan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack